A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

NCT04830644 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sjögren Syndrome

Interventions

DRUG: Iguratimod
DRUG: Placebo

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.